biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Post by AlfredSisleyon Jan 24, 2018 2:11pm

153 Views

Post# 27425425

Denali medical director heads to rival Alkahest

https://www.fiercebiotech.com/biotech/right-after-takeda-deal-denali-medical-director-heads-to-rival-alkahest

"Jonas Hannestad, M.D., Ph.D.—who is also adjunct assistant professor of psychiatry at Yale School of Medicine—is taking up the role of senior medical director at Alkahest, moving on from the medical director role he had at South San Francisco-based Denali."

Isn't Mark Day an adjunct assistant professor at Yale as well?

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading